# Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

> **NCT01550367** · PHASE1,PHASE2 · COMPLETED · sponsor: **Leonard Appleman** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT01550367
- **Lead sponsor:** Leonard Appleman
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2018-02-06
- **Final completion:** 2019-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01550367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01550367, "Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01550367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*